Combination Pasireotide and Pegvisomant in Acromegaly Combination Pasireotide and Pegvisomant in Acromegaly

Combined pasireotide and pegvisomant treatment may offer another approach for patients with acromegaly resistant to other treatment options.Journal of Clinical Endocrinology &Metabolism
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Related Links:

CONCLUSION: Patients with acromegaly have distinct lipid metabolite profiling while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications. PMID: 31930294 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
Clinicians'assessments of acromegaly symptom severity are often discordant with patients'self-reports, according to first survey of its kind. Better communication between docs and patients is needed.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Abstract CONTEXT: Reports on the incidence, characteristics, and comorbidity in Asian patients with acromegaly are scarce. OBJECTIVE: To evaluate the incidence of acromegaly and risk of comorbidities in East Asia, especially South Korea. DESIGN: This nationwide population-based cohort study using the Korean Health Insurance Review and Assessment Claims Database evaluated the incidence of acromegaly, initially diagnosed from 2010 to 2013. We identified comorbidities during, before, and 2 years after diagnosis. Acromegaly and control cases (718 and 7,180, respectively) were included in the analysis. S...
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
ConclusionResults further support the importance of achieving biochemical control, as this may reduce the risk of high-burden conditions, including diabetes and cardiovascular system disorders. The association for arthropathy suggests irreversibility of this impairment. Due to limitations, caution is required when interpreting these results.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
CONCLUSIONS: Elevated irisin levels in acromegalic subjects were associated with cIMT and EFT, suggesting that irisin is a surrogate marker for cardiovascular risk in acromegalic subjects. PMID: 31696447 [PubMed - as supplied by publisher]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
Growth hormone (GH) plays a significant role in normal renal function and overactive GH signaling has been implicated in proteinuria in diabetes and acromegaly. Previous results have shown that the glomerular podocytes, which play an essential role in renal filtration, express the GH receptor, suggesting the direct action of GH on these cells. However, the exact mechanism and the downstream pathways by which excess GH leads to diabetic nephropathy is not established. In the present article, using immortalized human podocytes in vitro and a mouse model in vivo, we show that excess GH activates Notch1 signaling in a γ-...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Molecular Bases of Disease Source Type: research
Purpose: Abnormal glucose metabolism is one of the most frequent acromegaly complications. Improvement of glucose metabolism can be observed only in half of acromegaly patients after surgery. We aimed to investigate the risk factors for determining abnormal glucose metabolism before surgery in patients with acromegaly, and to explore the predictors of improved preoperative glucose intolerance after surgery.Methods: We retrospectively reviewed 64 patients who received transsphenoidal surgery for acromegaly. Growth hormone (GH), insulin-like growth factor-1 (IGF-1) and glucose metabolism were assessed before, immediately aft...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Acromegaly is a clinical syndrome caused by excessive growth hormone. It is most commonly caused by a somatotroph adenoma of the anterior pituitary. It leads to soft tissue and bony overgrowth such as enlarged face, hands, feet, and tongue; coarsening of facial features; and development of diabetes and macroglossia. Duration of symptoms, from onset to diagnosis, is typically 12 years.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
Publication date: October 2019Source: Canadian Journal of Diabetes, Volume 43, Issue 7, SupplementAuthor(s): Julie-Catherine Coll, Nathalie Laflamme, Marie-Eve Domingue
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
More News: Acromegaly | Diabetes | Endocrinology | Health